SCHEMBL7039150

SCHEMBL7039150

O=c1[nH]c(-c2ccc(Cl)s2)nn1-c1cc(Cl)ccc1O

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 3/20 0.35
IDO1 P14902 1/20 0.35
CNR1 P21554 6/20 0.34
CNR2 P34972 6/20 0.34
PTGS1 P23219 2/20 0.33
ALOX5 P09917 1/20 0.33
ALDH1A1 P00352 1/20 0.32
CMA1 P23946 1/20 0.32
F10 P00742 1/20 0.32
PDE10A Q9Y233 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C19 P33261 1/20 0.31
KCNMA1 Q12791 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
DAO P14920 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7041687 0.88 AKT2 (0.35) PTGS2PTGS1ALOX5F10PDE10A
SCHEMBL7039913 0.88 CDK4 (0.33) PTGS2PTGS1ALOX5ALDH1A1F10
SCHEMBL7045380 0.88 SNCA (0.36) PTGS2IDO1CNR1CNR2PTGS1
SCHEMBL7039901 0.88 CNR1 (0.36) IDO1CNR1CNR2ALDH1A1CMA1
SCHEMBL7043650 0.84 IDO1 (0.34) IDO1ALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL7039107 0.83 IDO1 (0.35) IDO1ALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL7044160 0.82 IDO1 (0.33) IDO1ALDH1A1
SCHEMBL7042394 0.82 IDO1 (0.33) IDO1ALDH1A1
SCHEMBL7041119 0.82 LMNA (0.43) ALDH1A1MEN1KMT2A
SCHEMBL7043568 0.82 MEN1 (0.36) IDO1ALDH1A1CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6613786-B2 Treating urinary incontinence, asthma, irritable bowel syndrome or male erectile dysfunction BRISTOL-MYERS SQUIBB COMPANY 2003-09-02 US claimed
US-20030144333-A1 Thiophenyl triazol-3-one derivatives as smooth muscle relaxants HEWAWASAM PIYASENA (US) 2003-07-31 US claimed
US-6613786-B2 Treating urinary incontinence, asthma, irritable bowel syndrome or male erectile dysfunction BRISTOL-MYERS SQUIBB COMPANY 2003-09-02 US disclosed
US-20030144333-A1 Thiophenyl triazol-3-one derivatives as smooth muscle relaxants HEWAWASAM PIYASENA (US) 2003-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144333-A1 Thiophenyl triazol-3-one derivatives as smooth muscle relaxants PDE3A, ADRB2, ADRB3 PTGS2 139/4885IDO1 171/4885CNR1 416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.